4. Personalised Cancer medicine Flashcards

(54 cards)

1
Q

what does heterogeneous mean?

A

a tumour is made up of more the 1 cell type with different mutations.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

why are heterogeneous tumours bad?

A

they present an obstacle to treatment

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

are all tumour heterogenous?

A

no but most are especially metastatic tumours

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

why is relapse much more likely in heterogeneous tumours?

A

because not all cells in the tumour are killed by the treatment and the remaining cells can repopulate the tumour

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

why do we need personalised medicine?

A

current cancer treatment doesn’t account for the individual tumour and are broad specturm medicines

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

what current broad spectrum cancer treatments do we use?

A

drugs that target mitosis like taxol
these still have a role but they don’t differentiate between normal and tumour cells very well.
tumour cells are more susceptible to these treatments due to fast replication

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

what can personalised treatment do?

A

it accounts for specific mutations and can target them
each patient can have tailored treatment for their tumour with less side effects

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

what is an example of personalised cancer treatment?

A

if a tumour has BCR-ABL mutation specific drugs can be used to target it

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

what is BCR-ABL mutation?

A

it is a fusion protein made by chromosomal translocation from chromosome 9 and chromosome 22
it phosphorylates things that are not normally

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

what can effect different tumour biomarkers?

A

genetic and epigenetic factors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

what 2 cell types are all breast cancers derived from?

A
  1. luminal epithelial cells
  2. basal cells
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

what are the differences between luminal derived cancers and basal derived cancers?

A
  1. they responsed differently to signals
  2. they responsed differently to treatments
  3. basal cell cancers are normally receptor negative
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

what is basal luminal cell cancer?

A

a intermediate stage of cancer that tend to still have high levels of HER2 expression

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

what are 40% of luminal cancers?

A

Estrogen and progesterone receptor positive

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

what is triple negative breast cancer?

A

it makes up 15-20% of breast cancer
poor prognosis
Estrogen, progesterone and HER2 receptor negative
not as responsive to treatment

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

what does HER2 over expression lead to?

A

can be well treated with specific drugs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

what happens in estrogen receptor positive breast cancer?

A
  1. estrogen stimulates receptors
  2. activation of transcription factors
  3. causes cell proliferation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

how can we treat estrogen receptor positive breast cancer?

A
  1. tamoxifen blocks the binding of estrogen to the receptor
  2. prevents the cell proliferation signals
  3. used as a treatment to prevent cancer cell proliferation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

what is the HER2 receptor?

A

a tyrosine kinase that activates a number of kinase pathways

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

what can the HER2 tyrosine kinase pathways influence in the cancer cell?

A
  1. adhesion
  2. differentiation
  3. cell growth
  4. migration
  5. apoptosis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

how can we prevent HER2 signalling pathway stimulation?

A

using monoclonal antibodies like trastuzumab

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

what are the BRCA proteins involved in?

23
Q

what happens in DNA repair in normal cells?

A

there are lots of different DNA repair mechanisms and if one doesnt work then the other pathways can compensate

24
Q

what happens in BRCA1/2 DNA repair in tumour cells?

A
  1. either BRCA1 or BRCA2 pathways will be lost to start the cancer cell
  2. the cell is mutated enough that only 1 repair pathway left
  3. if we block the remaining repair pathway we can kill the cancer cells as the DNA becomes too damaged to replicate and survive
25
what is very common in HER2+ tumours?
amplification rather then mutation if the HER2 levels are high we can block the pathway
26
what is BRAF?
an oncogene mutation of BRAF is very common in skin cancer and other cancers
27
what are the 4 subtypes of medulloblastoma?
1. Wnt group 2. SHH group 3. Group 3 4. Group 4
28
what are Wnt group medullobastoma?
characterised by ß-catenin mutations metastasis is rare good prognosis
29
what are SHH group medullobastoma?
sonic the hedgehog group better survival in infants
30
what are group 3 medullobastoma?
frequent metastases MYC proto oncogene highly expressed
31
what are group 4 medullobastoma?
cyclin dependant kinase 6 amplification frequent metastases Minimal MYC expression high in infants
32
why is knowing the type of glioblastoma important?
it determines how you treat the patient. this is especially important in children.
33
what types of medulloblastoma need more aggressive treatment?
group 3 and 4 you would need early aggressive treatment Wnt group wouldn't need aggressive treatment
34
what does MGMT hypermethylation do in glioblastoma?
gene silencing to prevent DNA repair mechanism
35
what is unique about the MGMT assay?
it is one of the only DNA methylation based assays used in clinical settings
36
why is MGMT hypermethylation good in cancer treatment?
the cancers respond better the DNA damaging treatment
37
what is the drug most commonly used in MGMT hypermethylation therapy?
temozolomide - TMZ
38
what does temozolomide do?
it adds methyl groups to guanine which interferes with the rapid replication of tumour DNA and cause DNA damage
39
what does MGMT do?
it is part of our DNA repair mechanism
40
what does silencing MGMT do?
prevents DNA repair mechanisms so can force the cancer cells to apoptose after damages from TMZ
41
how is MGMT silenced?
using hyper methylation
42
when is MGMT sensitive to temozolomide?
when MGMT is silenced when MGMT is expressed at low levels
43
what are the 3 types of neuroblastoma histology?
1. Ganglioneruoma 2. ganglioneuroblastoma 3. neuroblastoma
44
Ganglioneruoma
generally benign ganglionic cells no need for aggressive treatment
45
neuroblastoma
high stage small undifferentiated cells very aggressive urgent strong treatment
46
what are neuroblastomas?
sympathetic nervous system cancer
47
what is MYCN?
a transcription factor strong association with MYCN amplification and poor prognosis very important in neuroblastoma
48
what is an experimental drug that can interfere with MYCN transcription?
JQ1 BRD4 it will bind to acetylated histones and at the MYCN promoter and start transcription. JQ1 binds BRD4 to prevent binding and prevent transcription
49
how do we know what personalised medicine to use?
sampling technologies
50
how do we determine tumour sensibility?
look for characteristics and features - take a sample - put in mice and try treatments - make a biobank from the mice - then recommend a suitable treatment
51
what are less invasive diagnositic techniques?
biomarkers liquid biopsies
52
what are liquid biopsies?
saliva cerebral spinal fluid blood and urine to find circulating tumour DNA/cells
53
what does these diagnostic tests look for?
gene fusion methylation changes Point mutations circulating mRNA
54
what is pharmacogenomics?
cancer genome sequencing that can inform choice of selective therapies